Skip to main content

New Selenium-based Targeted Nanocapsules to treat Breast Cancer

Objective

The European Chronic Diseases Alliance has defined cancer as one of the major non-communicable diseases, accounting
for 13% of the deaths worldwide, resulting in 8.2 million deaths annually. In the NEOSETAC project, breast cancer will be the
focus of study being the most common cancers in women. It comprises of 10.4% of all the cancer incidences among women,
causing 411 093 deaths per year overall the world. In Europe, there is more than twice of the amount of new breast cancer
cases annually than new cases of cancer in any other place. The complexity of breast cancer makes it a big challenge for
successful treatment. The NEOSETAC project will demonstrate the anti-cancer therapeutic potential of a novel Seleniumbased
therapy for the management of breast cancer. The clinical application of Selenium (Se) compounds for cancer
treatment is until now limited in chemoprevention as dietary supplement. In this proposal, we aim to improve the therapeutic
window, pharmacokinetic properties and targeting drug delivery via nanoparticles (NPs). By loading Se into biodegradable
NPs, drug release is controlled within the narrow therapeutic window of Se. At the same time the uptake and activation of Se
compounds at desired location (tumor lesions and metastasis) is achieved. We also propose to functionalize NPs by cancer
cell / cancer stem cell targeting ligands to further improve the therapeutic efficacy and prevent cancer recurrence after
chemotherapy. These advantages will lead to an enhanced anticancer activity and reduced systemic toxicity. Moreover,
targeting via NPs will improve the pharmacokinetic properties and increase the relatively short half-life (~18 hours) of Se.

Field of science

  • /medical and health sciences/medical biotechnology/cells technologies/stem cells
  • /natural sciences/chemical sciences/inorganic chemistry/inorganic compounds
  • /medical and health sciences/clinical medicine/oncology/cancer
  • /medical and health sciences/clinical medicine/oncology/cancer/breast cancer

Call for proposal

H2020-MSCA-RISE-2017
See other projects for this call

Funding Scheme

MSCA-RISE - Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE)

Coordinator

UNIVERSIDAD AUTONOMA DE BARCELONA
Address
Calle Campus Universitario Sn Cerdanyola V
08290 Cerdanyola Del Valles
Spain
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 171 000

Participants (6)

KAROLINSKA INSTITUTET
Sweden
EU contribution
€ 171 000
Address
Nobels Vag 5
17177 Stockholm
Activity type
Higher or Secondary Education Establishments
ACIB GMBH
Austria
EU contribution
€ 54 000
Address
Krenngasse 37/2
8010 Graz
Activity type
Research Organisations
AB BCN S.L.
Spain
EU contribution
€ 45 000
Address
Lg Bellaterra Parc De Recerca
08193 Cerdanyola Del Valles
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
QUALIZYME DIAGNOSTICS GMBH & CO KG

Participation ended

Austria
EU contribution
€ 0
Address
Neue Stiftingtalstrasse 2
8010 Graz
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
REGION STOCKHOLM
Sweden
EU contribution
€ 27 000
Address
Hantverkargatan 45
104 22 Stockholm
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
ADSI-AUSTRIAN DRUG SCREENING INSTITUTE GMBH
Austria
EU contribution
€ 36 000
Address
Innrain 66A
6020 Innsbruck
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)